Recro Pharma’s shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker’s non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.
The U.S. FDA issued warning letters to three companies that illegally marketed and distributed products containing the substance kratom, which they claimed treat opioid addiction and withdrawal.
Alkermes Plc was told to conduct more clinical trials of the company’s experimental depression treatment after the U.S. Food and Drug Administration rejected its initial application for approval.
Shares in Britain’s Indivior were hammered on Friday after the company lost a second legal case in recent months in an attempt to protect the patent of an opioid addiction treatment that generates 80 percent of its revenues.
The Food and Drug Administration is seeking public opinion as well as scientific research on the role nicotine plays in cigarette addiction as the regulatory agency aims to lower tobacco-related deaths across the United States.
Heavy drinkers may be more likely than other adults to develop dementia, especially in middle age, a French study suggests.
Britain’s Indivior is launching a new weapon to fight the U.S. opioid crisis this month, but high hopes for its once-monthly injection were offset on Thursday by the need to set aside more cash for legal disputes.
Life expectancy in the United States dipped in 2016 as the number of deaths due to opioid drug overdoses surged and total drug overdose deaths rose 21 percent to 63,600, the U.S. Centers for Disease Control and Prevention said.
Jeremy Perrott, McCann Health Global Chief Creative Officer, created the film that is meant to be a wake-up call that delivers a shocking moment of truth, like a stinging slap across the face. The visual style of filming the teenage boy’s first-person point of view, delivers an immersive and immediate experience that shines a light on the danger of what can happen if parents do not take steps to create a prescription drug safe home.
The FDA accepted Indivior’s application for its new once-monthly injectable schizophrenia treatment.